By Modupe Gbadeyanka
Leader in cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, ResMed, has entered a definitive agreement to acquire Propeller Health, a digital therapeutics company providing connected health solutions for people living with chronic obstructive pulmonary disease (COPD) and asthma.
Named a 2017 Most Innovative Company by Fast Company, Propeller helps people and their doctors better manage their COPD and asthma.
Propeller’s digital medicine platform consists of small sensors that easily attach to consumers’ inhalers and pair with a mobile app to automatically track medication use and provide personal feedback and insights.
Its clinically validated solutions have demonstrated a 58 percent improvement in medication adherence, 48 percent increase in symptom-free days and 53 percent reduction in emergency room visits.
Propeller’s ability to support people in stage II and III severity levels of their COPD are complementary to ResMed’s own suite of cloud-connected ventilators for those with stage III and IV COPD, including Astral, Stellar and AirCurve 10 ST-A with iVAPS – plus ResMed’s new portable oxygen concentrator Mobi.
“Acquiring Propeller is a significant step for ResMed toward becoming the global leader in digital health for COPD,” said ResMed CEO Mick Farrell. “By working with Propeller’s existing partners to offer digital solutions for respiratory care pharmaceuticals and building on our proven ability to support digital solutions at scale, we can positively impact the lives of even more of the 380 million people worldwide who are living with this debilitating chronic disease.”
“Helping inhaler users improve adherence and avoid hospitalizations perfectly serves ResMed’s mission: to improve people’s quality of life, reduce the impact of chronic disease and save healthcare costs across the out-of-hospital care spectrum,” said ResMed Respiratory Care President Richie McHale.
“ResMed shares our belief that connected health solutions create vastly better experiences and outcomes for people with chronic respiratory disease,” said David Van Sickle, co-founder and CEO of Propeller. “Joining forces enables us to accelerate the adoption of Propeller’s solutions at a global scale, and serve as a powerful platform for a broad set of pharmaceutical and healthcare partners.”
Propeller is privately funded, and based in Madison, Wisconsin, with an office in San Francisco. It will continue to operate as a standalone business within ResMed’s Respiratory Care portfolio. There will be no immediate changes to management, locations or business processes. Van Sickle will continue in his current role, now reporting to McHale.
Under the agreement terms, ResMed will acquire Propeller for $225 million, which ResMed will fund primarily with its credit facility. Upon closing, the transaction is expected to have a dilutive impact on ResMed’s quarterly non-GAAP earnings per share in the range of $0.01 to $0.02 during Fiscal Year 2019.
ResMed and Propeller expect to finalize the deal before the end of the third quarter of ResMed’s fiscal year 2019 (March 30, 2019), subject to customary closing conditions, including regulatory approvals.
Health Insurance for all Nigerians by 2030 Now Realistic—NHIA
By Adedapo Adesanya
The National Health Insurance Authority (NHIA) has commended President Muhammadu Buhari for signing into law the NHIA Act, saying health insurance for all Nigerians by 2030 is now more realisable.
The NHIS Deputy General Manager, Mr Emmanuel Ononokpono, in a statement said, “For over two decades, industry professionals had sustained the call for an amendment to the health insurance law, being a major impediment to the attainment of Universal Health Coverage (UHC).
“By this development, efforts to tackle the high incidence of poverty caused by out-of-pocket expenses for health care, through health insurance for all categories of Nigerians by 2030, is now more realisable than ever before.”
Mr Ononokpono also said that the management was also grateful to the Senate and the House of Representatives for their roles in the lead up to the enactment of the law.
He acknowledged the roles played by different stakeholders in the course of the legislative work on the law.
According to him, the Act establishes and empowers the NHIA to ensure the provision of health insurance for all Nigerians through a mandatory mechanism, in collaboration with state health insurance agencies.
He said that sections 25 and 26 of the Act established the Vulnerable Group Fund (VGF), indicating the various sources from which funding would be drawn.
Mr Ononokpono said that the legislation strengthened the NHIA to discharge a wide range of regulatory and promotion functions, to ultimately ensure that every Nigerian received access to quality and affordable health care.
He said that the legislation Mr Buhari assented to did not make provision for a telecommunications tax as a source of funding in the law, contrary to reports in some national media.
Mr Ononokpono also urged stakeholders and industry players, including the media to wait for a formal unveiling of the document.
President Buhari signed the National Health Insurance Authority Bill 2021 last week.
The newly signed law by the President repeals the National Health Insurance Scheme Act 2004.
Under the previous Act, states were required to pay a 50 per cent counterpart fund to access the total fund for the Basic Healthcare Provision Fund (BHCPF).
Explainer: What is Monkeypox Virus?
By Adedapo Adesanya
In a world where the coronavirus is still around, attention may shift to the Monkeypox virus – which has been found in Australia, the United States, and some top countries in Europe.
What is the Monkeypox Virus?
According to a World Health Organisation (WHO) research, the Monkeypox virus is a virus that is transmitted to humans from animals. The first case was discovered back in a small child back in 1970 in the Democratic Republic of the Congo.
It is a rare disease caused by the monkeypox virus, part of the same family as smallpox, though typically less severe. The incubation period of the newly spreading Monkeypox virus ranges from 6 to 13 days. However, it might be from 5 to 21 days.
Symptoms such as fever, intense headache, lymphadenopathy, back pain, myalgia (muscle aches), and an intense asthenia (lack of energy) usually appear in the patients who test positive for the Monkeypox virus. On the other hand, skin eruption usually starts within 1-3 days of the appearance of fever. The rash appears mostly on the face and extremities rather than on the chest.
History in Nigeria
There have since been sporadic cases reported across 10 African countries, including Nigeria, which in 2017 experienced the largest documented outbreak, with 172 suspected and 61 confirmed cases. In terms of age, 75 per cent of those affected were males aged 21 to 40 years old.
Cases outside of Africa have historically been less common and typically linked to international travel or imported animals.
How Can One Catch Monkeypox?
Monkeypox spreads when someone comes into close contact with another person, animal or material infected with the virus. The virus can enter the body through broken skin, the respiratory tract or through the eyes, nose and mouth. Human to human transmission most commonly occurs through respiratory droplets, though usually requires prolonged face-to-face contact.
Animal to human transmission meanwhile may occur via a bite or scratch but the disease is not generally considered a sexually transmitted disease, though it can be passed on during sex.
There are currently no proven, safe treatments for monkeypox, though most cases are mild. In the past, researchers said that vaccination against smallpox with the vaccinia vaccine was proved through several observational studies to be about 85 per cent effective in preventing the Monkeypox virus.
A newer vaccinia-based vaccine was approved for the prevention of smallpox and monkeypox in 2019 and is also not yet widely available in the public sector. Countries including the United Kingdom and Spain are now offering the vaccine to those who have been exposed to infections to help reduce symptoms and limit the spread.
Can it Kill?
Monkeypox cases can occasionally be more severe, with some deaths having been reported in West Africa. However, health authorities stress that we are not on the brink of a serious outbreak and the risks to the general public remain very low.
What are Health Regulators Saying?
WHO says it continues to closely monitor as the situation is evolving rapidly. It is supporting member states with surveillance, preparedness, and outbreak response activities for monkeypox in affected countries.
Health authorities in the United Kingdom, the United States, and Canada urged people who experience new rashes or are concerned about monkeypox to contact their healthcare provider.
WHO also clarified that does it not recommend any restrictions for travel based on available information at this time.
Malaria: Nova Diamond Launches Give A Net Campaign
By Adedapo Adesanya
In commemoration of World Malaria Day for the year 2022, Nova Diamond Foundation has launched a campaign called Give a Net, ave Lives.
The Give a Net campaign is targeted to protect the most vulnerable in society, including pregnant women and children under the age of 5 because of the increased death rate, according to WHO 2021 Malaria report.
WHO described malaria as the 3rd highest killer non-communicable disease as the disease kills four in every five malaria cases in Nigeria. Malaria is the number one endemic in the country, which also has the highest number of malaria-related deaths.
To address this issue and reduce malaria-related deaths, Nova Diamond Foundation has partnered with the Lagos State Ministry of Health to educate residents on the danger posed by malaria.
The organisation also worked in partnership with Mobaby Care to walk the streets of Lagos, starting with Agboyi LCDA under Kosofe LGA, Mascara Primary Health Centre and Alapere Primary Health Centre, Ketu. These health facilities were visited between Monday, April 25 and Wednesday, April 27, 2022.
During the visits, pregnant mothers and children were given some malaria prevention incentives like Insecticides Treated Nets (ITNS) and mosquito repellant creams from Mobaby Care.
The executive director of Nova Diamond Foundation, Mrs Oluwafikayo Ooju, sensitised the participants on how to protect their unborn children, toddlers and themselves from malaria by ensuring that they always sleep under an insecticide-treated net.
She also lectured them on keeping their environment clean from stagnant water, ensuring children are well covered up and use of repellant to the exposed parts of the body.
In addition, she educated them on how to identify the symptoms of malaria as well as the need to visit the primary health centres for proper diagnosis and treatment immediately after they notice any symptoms.
In her remarks, the Medical Officer in charge of Agboyi LCDA, Dr Mariam Oshodi, commended the effort of the foundation and also advised the beneficiaries to use all the incentives distributed to them.
The team intends to visit other primary health centres across Lagos state and hopes to reach at least 1,000 pregnant mothers and 1000 children aged 0-5.
Latest News on Business Post
- ICAN, BOI Partner to Drive Stakeholders Inclusion in Tech May 25, 2022
- Lagos Guber: Group Alleges Plot to Disqualify Mustapha May 25, 2022
- Access Bank Deploys Strategies to Dominate Agency Banking May 25, 2022
- Chelsea £4.25bn Takeover Complete as UK, Abramovich Agree May 25, 2022
- Nigeria’s Crude Oil Refining Capacity to Hit 1.2 million bpd in 5 Years—NCDMB May 25, 2022
- 80% of Buhari’s Ministers, Appointees Grossly Incompetent—CNPP May 25, 2022
- Identity Management System Will Reduce Unclaimed Dividends—SEC May 25, 2022
- LBS, NowNow Unveil Financial Literacy Initiative May 25, 2022
- CSCS Lifts Unlisted Securities Market by 0.24% May 25, 2022
- Naira Appreciates at I&E Amid 1.3% Rise in FX Transactions May 25, 2022